Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-20-002949
Filing Date
2020-11-13
Accepted
2020-11-13 17:27:53
Documents
1

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13D sc13da207422fprx_11132020.htm SC 13D/A 290759
  Complete submission text file 0000921895-20-002949.txt   292452
Mailing Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Business Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

EIN.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice

Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Subject) CIK: 0001175505 (see all company filings)

EIN.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87623 | Film No.: 201312713
SIC: 2834 Pharmaceutical Preparations